Pemphigus Vulgaris (PV) Market Insights, Epidemiology & Forecast to 2027 - ResearchAndMarkets.com

DUBLIN--()--The "Pemphigus Vulgaris (PV) - Market Insights, Epidemiology and Market Forecast-2027" drug pipelines has been added to ResearchAndMarkets.com's offering.

The market of Pemphigus Vulgaris (PV) in 7MM was found to be USD 74.03 million in 2016, and is expected to increase from 2016-2027.

This report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Pemphigus Vulgaris (PV) in the United States, EU5, and Japan.

The Pemphigus Vulgaris epidemiology division provide the insights about historical and current patient pool and forecasted trend for each of the 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

According to this research, total prevalent population of Pemphigus Vulgaris in 7 major markets was estimated to be 62,747 in 2016.

This segment of the Pemphigus Vulgaris report encloses the detailed analysis of marketed drugs and late stage pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Companies Mentioned

  • Novartis Pharmaceuticals
  • Hoffmann-La Roche
  • Principia Biopharma, Inc.
  • Argenx

Key Topics Covered:

1. Key Insights

2. Pemphigus Vulgaris Market Overview at a Glance

3. Disease Background and Overview: Pemphigus Vulgaris (PV)

4. Epidemiology and Patient Population

5. Country Wise-Epidemiology of Pemphigus Vulgaris (PV)

6. Treatment Algorithm

7. Unmet needs

8. Emerging Therapies

9. Discontinued Drug

10. Inactive Drug

11. Pemphigus Vulgaris: Market Analysis

12. Market Size of Pemphigus Vulgaris by Country

13. Market Drivers of PV

14. Market Barriers of PV

15. Appendix

16. Report Methodology

17. Capabilities

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/g4s8k9/pemphigus?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Immune Disorders Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Immune Disorders Drugs